This roundtable series discusses when to use chemotherapy and best dosing practices in patients with metastatic castration-resistant prostate cancer after treatment with docetaxel, as discussed by participants at virtual live events.
CARD Trial Shows Survival and QOL Benefits of Cabazitaxel in mCRPC
June 15th 2022During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.
VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPC
July 5th 2022During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.
Discussing the Role of Cabazitaxel Post–Hormone Therapy for mCRPC
November 30th 2022During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.
Considerations on Tolerability of Cabazitaxel in mCRPC
December 16th 2022During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants their experiences with using cabazitaxel in patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
Physicians Discuss the Addition of Cabazitaxel to Treatment in mCRPC
June 20th 2023In the first of a 2-part article series, Joshua Lang, MD, and live event participants discuss how the addition of cabazitaxel to the treatment of patients with metastatic castration-resistant prostate cancer can improve outcomes despite some challenging adverse events.
Physicians Discuss Targeted Treatment for Prostate Cancer Subtypes
July 10th 2023In the second article of a 2-part article series, Joshua Lang, MD, and live event participants discuss the role of cabazitaxel for the treatment of patients with prostate cancer who harbor certain mutations or have other factors that make their disease unique.
Safety Results with Cabazitaxel Support Wider Use in mCRPC
September 8th 2023In the second article of a 2-part series, Mehmet A. Bilen, MD, explains how further findings from the phase 3 CARD trial support the wider role cabazitaxel should have in treating patients with metastatic castration-resistant prostate cancer.